Zweijährige Interferon-Therapie eines metastasierten Carcinoids

Scheidt, Wolfgang von; Böhm, Michael; I, Huber; Habersetzer, R; Jacob, K.; Markl, A; Autenrieth, G

doi:10.1007/bf01662725

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon ␣ (IFN␣) and octreotide are not only useful for controlling symptoms, they have both caused tumor stabilization or regression [55,56]. In one case tumor growth occurred when (IFN␣) treatment was withheld, and the tumor regressed when therapy was reinstituted [55].…”

Section: Medical Treatmentmentioning

confidence: 99%

Pulmonary and Thymic Carcinoid Tumors

1996

View full text Add to dashboard Cite

Carcinoid tumors of the lung and bronchi are usually benign lesions with no influence on life expectancy, although occasionally, they are malignant with a poor prognosis. Between these two extremes are atypical carcinoids, which can be slow-growing tumors with an average 5-year survival of 60% and an average 10-year survival of 40%. The myriad names used to describe these lesions complicates the understanding of their behavior, especially as the term carcinoid is used to describe the complete spectrum of disease or exclusively the benign well differentiated lesions with an excellent prognosis. Thymic carcinoids are uncommon lesions. Their prognosis is poor, even in cases that appear favorable in terms of resectability and histology. Pulmonary carcinoids present uncommonly with a paraneoplasic syndrome. Both carcinoid and Cushing syndromes are seen with approximately 2% of these lesions. Cushing syndrome can be present in as many as one-third of patients with thymic carcinoids but an association with the carcinoid syndrome has never been described.

show abstract

Section: Medical Treatmentmentioning

confidence: 99%

Pulmonary and Thymic Carcinoid Tumors

1996

View full text Add to dashboard Cite

show abstract

“…These agents can offer good symptomatic relief, and in some cases, tumor stabilisation or regression can be seen [41][42][43][44][45]. In one case, omission of a-interferon led to tumor progres sion which was reversible when treatment was reinsti tuted [44]. Octreotide has also been used successfully for the treatment of carcinoid storm and for its prevention or treatment during surgery [41][42][43], Hepatic artery ligation alone or in association with chemotherapy has also of fered relief from carcinoid syndrome [42], Octreotide has also occasionally been successful in relieving Cushing's syndrome due to ectopic ACTH secretion.…”

Section: Treatmentmentioning

confidence: 99%

Bronchial and Thymic Carcinoid Tumors: A Review

Dusmet

McKneally²

1994

Digestion

View full text Add to dashboard Cite

Bronchial carcinoid tumors are usually indolent, slow-growing tumors with an excellent prognosis. However, even typical carcinoids can metastazise to regional lymph nodes or to distant sites. Atypical carcinoids tend to behave more invasively with more frequent nodal and distant metastases. Despite this, long-term survival can be expected as many tumors grow and spread slowly. At the end of the spectrum are the highly aggressive small cell carcinomas which have a very poor prognosis despite aggressive chemotherapy. Clinically, carcinoid tumors are frequently asymptomatic. Symptoms are most frequently due to obstruction (pneumonia, ‘asthma’, coughing) or bleeding. Carcinoid syndrome is seen infrequently and usually signifies metastatic disease. Cushing’s syndrome is occasionally seen in association with these tumors. The treatment of carcinoid tumors is surgical. Resection should be complete and encompass the regional lymph nodes.

show abstract

The interferons. Mechanisms of action and clinical applications

et al. 1991

JAMA: The Journal of the American Medical Association

375

177

View full text Add to dashboard Cite

The interferons (IFN) are one of the body's natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (alpha, beta, and gamma), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi's sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs alpha and beta and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.

show abstract

Zweijährige Interferon-Therapie eines metastasierten Carcinoids

Cited by 3 publications

References 24 publications

Pulmonary and Thymic Carcinoid Tumors

Pulmonary and Thymic Carcinoid Tumors

Bronchial and Thymic Carcinoid Tumors: A Review

The interferons. Mechanisms of action and clinical applications

Contact Info

Product

Resources

About